Find Funding Opportunities

Find Funding Opportunities

Returning 167 results
Filter By:

Discovery of Biomarkers and Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)

PAR
Wednesday, July 10, 2019
Tuesday, March 8, 2022
R61/R33
PAR-19-315

Funding Opportunity Purpose

The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders. Although research supported by this FOA can include animal studies, it must also include preliminary human evaluation using carefully standardized human samples or datasets. The goal of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.

Molecular Mechanisms of Blood-Brain Barrier Function and Dysfunction in Alzheimer's disease and Alzheimer's related dementias (AD/ADRD) (R01 Clinical Trial Not Allowed)

RFA
Wednesday, July 10, 2019
Thursday, October 10, 2019
R01
RFA-NS-20-004

Funding Opportunity Purpose

The goal of this initiative is to elucidate the mechanistic links between blood brain barrier (BBB) dysfunction, Alzheimers disease (AD) and AD-related dementias (ADRD), and how related comorbidities impact the basic molecular mechanisms of BBB health and function.

BRAIN Initiative: Non-Invasive Neuromodulation - New Tools and Techniques for Spatiotemporal Precision (R01 Clinical Trial Optional)

RFA
Thursday, June 27, 2019
Saturday, February 15, 2020
R01
RFA-MH-20-310

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) solicits grant applications in two related but distinct areas. The first area is in the development and testing of novel tools and methods of neuromodulation that go beyond the existing forms of neural stimulation. The second distinct area that this FOA seeks to encourage is the optimization of existing stimulation methods.

BRAIN Initiative: Development of Next Generation Human Brain Imaging Tools and Technologies (U01 Clinical Trial not allowed)

RFA
Thursday, June 27, 2019
Saturday, September 4, 2021
U01
RFA-EB-19-002

Funding Opportunity Purpose

This funding opportunity announcement (FOA), in support of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, aims to support full development of entirely new or next generation noninvasive human brain imaging tools and methods that will lead to transformative advances in our understanding of the human brain. The FOA seeks innovative applications that are ready for full-scale development of breakthrough technologies with the intention of delivering working tools. This FOA represents the second stage of the tool/technology development effort that started with RFA-MH-14-217 and RFA-MH-15-200

BRAIN Initiative: Proof of Concept Development of Early Stage Next Generation Human Brain Imaging (R01 Clinical Trial Not Allowed)

RFA
Thursday, June 27, 2019
Wednesday, September 4, 2019
R01
RFA-EB-19-001

Funding Opportunity Purpose

This funding opportunity announcement (FOA), in support of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, aims to support early stage development of entirely new and novel noninvasive human brain imaging technologies and methods that will lead to transformative advances in our understanding of the human brain. The FOA solicits unusually bold and potentially transformative approaches and supports small-scale, proof-of-concept development based on exceptionally innovative, original and/or unconventional concepts.

NINDS Child Neurologist Career Development Program (CNCDP) (K12 Clinical Trial Not Allowed)

RFA
Thursday, June 27, 2019
Wednesday, September 11, 2019
K12
RFA-NS-19-040

Funding Opportunity Purpose

The purpose of the NINDS Child Neurologist Career Development Program (CNCDP) is to facilitate and support the research career development of child neurologists who have made a commitment to independent research careers. The CNCDP is a single national program, implemented by one or more PD/PIs and, if applicable, co- directors (at least one of whom is the PD/PI), together with an advisory committee composed of basic and clinical investigators who have a strong record of funded research and successful training of clinician scientists. The CNCDP will generally provide three consecutive years of support to individuals to provide them with the knowledge, tools and research experience that will enable them to develop a significant research project funded by an individual career development award or research grant. This Funding Opportunity Announcement (FOA) does not allow appointed scholars to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

BRAIN Initiative: Marmoset Coordination Center (U24 Clinical Trials Not Allowed)

RFA
Tuesday, June 25, 2019
Saturday, October 19, 2019
U24
RFA-MH-20-150

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) solicits applications to create a Marmoset Coordination Center. The awardee will be responsible for two separate but related activities. The first activity will be to become the repository for genomic, pedigree, and event records (date of birth, medical, reproductive history) for captive marmosets. The awardee is expected to use that information to help make breeding recommendations to maximize the health and genetic diversity of the marmosets in primate colonies. Applicants are encouraged to adopt the model used by the Association of Zoos and Aquariums.

BRAIN Initiative: Marmoset Colonies for Neuroscience Research (U24 Clinical Trials Not Allowed)

RFA
Tuesday, June 25, 2019
Friday, October 4, 2019
U24
RFA-MH-20-145

Funding Opportunity Purpose

The common marmoset has recently emerged as a promising model system to understand the primate brain. In particular, marmoset behavior is similar in many ways to human behavior and the technology for germ line transmission of exogenous genetic information is now possible. However, existing colonies and commercial sources are currently unable to provide sufficient marmosets for neuroscience research.

Mechanistic Basis of Diffuse White Matter Disease in Vascular Contributions to Cognitive Impairment and Dementia (VCID)(R01 Clinical Trial Not Allowed)

RFA
Friday, June 14, 2019
Thursday, August 15, 2019
R01
RFA-NS-19-039

Funding Opportunity Purpose

(Reissue of RFA-NS-16-021, PAR-18-413) Diffuse brain white matter disease is highly prevalent in the elderly, and has been clinically associated with vascular contributions to cognitive impairment and dementia (VCID) in both men and women. Diffuse white matter disease is thought to include a variety of pathologies including demyelination and/or fiber loss due to multifocal infarction and local ischemia. It is often accompanied by arteriosclerosis in deep penetrating arteries, multiple infarcts in the basal ganglia, brainstem or cerebellum. Though most commonly extending out from the periventricular surfaces, it may also occur in subcortical white matter. Diffuse white matter disease is typically detected in clinical settings as hyperintensity on magnetic resonance imaging (MRI) or signal loss on computed tomography x-ray (CT) scan; diffuse white matter disease can be detected histologically as well, for example in human pathology and in studies using animal models. Despite the prevalence and potential significance of white matter disease for cerebrovascular disease etiology and cognitive outcomes, much remains to be learned about the cellular and molecular causes, regional vulnerability, and progression over time. The physiological consequences of diffuse white matter disease on local axon and neural circuit function are almost completely unknown. The purpose of this FOA is to address some of the many gaps in knowledge of the biologic mechanisms of the commonly occurring, cerebrovascular disease and age-related diffuse white matter disease at the molecular, cellular, tissue and brain circuit level. The ultimate goal of this fundamental research is to inform future efforts to reduce the burden of illness due to age-related vascular contributions to cognitive impairment and dementia.

Brain Initiative: Research to Develop and Validate Advanced Human Cell-Based Assays To Model Brain Structure and Function (R01 Clinical Trial Not Allowed)

RFA
Friday, May 31, 2019
Saturday, November 2, 2019
R01
RFA-MH-20-140

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. This includes technologies that do not rely on the use of human fetal tissue, as described in NOT-19-042. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states.

Pages